Compare iShares MBS ETF (MBB) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Revvity Inc — how do they compare? iShares MBS ETF trades at $89.75 (market cap $35.41B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: iShares MBS ETF is far larger — about 2.1× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while iShares MBS ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 96 Days and Revvity Inc for 12 Days on average.
| MBB | RVTY | |
|---|---|---|
Market Cap | $35.41B | $16.98B |
Volume | 5,388,525 | 1,456,900 |
Sector | Fixed Income | Health |
52-Week High | $96.91 | $157.36 |
52-Week Low | $89.09 | $82.26 |
Typical Hold Time | 96 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB (iShares MBS ETF) trades at $89.79, up 0.64% with bearish technical signals from moving averages and ADX indicators. The ETF faces headwinds from rising intermediate-term rates and inflation pressures, with short interest surging 98.3% in September. Recent institutional buying by Corient Private Wealth and Baird Financial contrasts with technical weakness and negative analyst commentary on duration risk.
Outlook remains cautious due to interest rate sensitivity and convexity risks in mortgage-backed securities. The 5.68-year effective duration exposes MBB to Fed policy shifts, though Norway's $2.3 trillion sovereign fund rotation into MBS provides counterbalancing institutional support. Key risks include prepayment optionality and persistent inflation eroding real returns.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
